eLeaflet is a digital drug leaflet solution from myHealthbox, aimed at pharmaceutical, medical device, and health product companies. It is designed for creating, managing, and distributing verified, official, and continuously updated information for medicines and healthcare products. The product emphasizes the shift from paper leaflets to digital leaflets, and supports access by patients, pharmacists, and healthcare professionals via methods such as QR codes.
The platformβs core capabilities include digital leaflet management, eIFU distribution, multilingual and multi-country localization, multi-batch management, real-time updates, and support for multimedia content. In terms of formats, the official website mentions native support for semi-structured data and compatibility with common XML-like formats such as ePI, JPL, SPL, XML PM, and HTML. For barcodes, it supports QR code, GTIN, GS1 Data Matrix, and GS1 Digital Link, making it suitable for packaging, labeling, and production-line scenarios. The myHealthbox distribution platform can be used for content lookup and publishing official information.
The official website does not disclose pricing or plans and only provides a contact form, so procurement appears to be more enterprise-customized. For deployment, it mentions a fully-managed eLeaflet As A Service model, where the provider is responsible for design, management, distribution, and updates, but it does not state whether private deployment is supported. Security and compliance are major selling points: it supports secure distribution via HTTPS/SSL, digital signatures, and is described as validated according to FDA 21 CFR Part 11 and EMA GMP Annex 11 requirements. It also mentions GMP validated status, as well as specific approved use cases for digital leaflets/bilingual leaflets in Brazil and Italy.
Its strengths are its strong vertical focus on the industry, covering the formats, barcodes, multilingual capabilities, and compliance elements needed for digitizing drug leaflets. It is well suited to multinational pharmaceutical companies and scenarios with strict regulatory requirements. The fully-managed model can also reduce the implementation burden on internal enterprise teams. The downside is that the publicly available information is not very complete: there is no pricing, SLA, API, permission model, approval workflow, audit log, data residency, or cloud region information, making it difficult to complete a technical evaluation based only on the official website.
It is better suited to pharmaceutical companies, medical device companies, health product companies, regulatory affairs teams, product managers, and national drug regulators for official leaflet digitization, eIFU distribution, and QR code access from packaging. Accessibility from China cannot be determined from the available text, and payment methods are not disclosed. If targeting the Chinese market, key points to verify include network accessibility, Chinese localization, cross-border data handling, pharmaceutical regulatory compliance, and integration capabilities with domestic drug traceability/content management systems.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on eleaflet.eu official site.
eleaflet.eu is an EU SaaS Tools provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach eleaflet.eu directly.